Holen Sie sich die Stockscreener-App
1.60
0.62%
-0.01
Whitehawk Therapeutics Inc Aktie (WHWK) Neueste Nachrichten
WHWK Stock Sees Surge of Approximately 10.60% in Last Five Days - knoxdaily.com
Should You Expect A Quick Recovery From Whitehawk Therapeutics Inc (NASDAQ: WHWK) After -128.14% Decline From High? – Marketing Sentinel - Marketing Sentinel
Whitehawk Therapeutics Inc: Navigating Market Fluctuations with a 73.92M Market Cap - investchronicle.com
A review of WHWK’s current quarter earnings predictions - uspostnews.com
Whitehawk Therapeutics - The Pharma Letter
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations - MarketScreener
Aadi Bioscience to Participate at Upcoming Investor Conferences - MarketScreener
Aadi Bioscience to Participate in Upcoming Investor Events - MarketScreener
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - MarketScreener
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting - MarketScreener
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference - MarketScreener
Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes - MarketScreener
Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $5.2M - MarketScreener
Whitehawk Therapeutics, Inc. SEC 10-K Report - TradingView
Kaken Pharmaceutical Co., Ltd. entered into a stock purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for $100 million. - marketscreener.com
Whitehawk Therapeutics Closes Sale of Aadi Subsidiary to Kaken Pharmaceuticals - citybiz
Whitehawk Therapeutics sells subsidiary for $102.4 million By Investing.com - Investing.com South Africa
Whitehawk Therapeutics sells subsidiary for $102.4 million - Investing.com India
Whitehawk sells Aadi Subsidiary to Kaken for $100 million - Investing.com
Whitehawk sells Aadi Subsidiary to Kaken for $100 million By Investing.com - Investing.com India
Whitehawk Therapeutics Completes Strategic Transformation With Successful Closing Of Sale Of Aadi Subsidiary To Kaken Pharmaceuticals - Marketscreener.com
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals - The Victoria Advocate
Whitehawk's $200M Double Win: Strategic Sale Plus PIPE Funding Fuels ADC Future - Stock Titan
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing - MarketScreener
Aadi Bioscience Announces Participation in Upcoming September Investor Conferences - MarketScreener
Aadi Bioscience Announces Leadership Transition - MarketScreener
Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium - MarketScreener
Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2024 Earnings Call Transcript - Insider Monkey
Aadi Bioscience’s Earnings Call: Strategic Shifts and Promising Pipeline - TipRanks
Aadi Bioscience, Inc. Appoints Baiteng Zhao to its Board of Directors - MarketScreener
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update - Marketscreener.com
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update - MarketScreener
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update - Marketscreener.com
Aadi Bioscience, Inc. Announces CEO Changes - MarketScreener
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) - Marketscreener.com
Aadi Bioscience to Participate in the Jefferies Healthcare Conference - MarketScreener
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer - MarketScreener
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders - Marketscreener.com
Aadi Bioscience Inc (AADI) Q4 2024 Earnings Call Highlights: Strategic Transition and Financial ... By GuruFocus - Investing.com Canada
Whitehawk Therapeutics: Strategic Shift and Financial Outlook - TipRanks
Aadi rebrands as Whitehawk Therapeutics in new ADC focus - The Pharma Letter
Novartis cuts over 400 jobs ahead of Entresto patent loss - The Pharma Letter
Six new option listings and four option delistings on March 19th - TipRanks
Aadi Bioscience, Inc. will Change its Name to Whitehawk Therapeutics, Inc -March 19, 2025 at 12:00 am EDT - Marketscreener.com
Aadi Bioscience Inc changes name to Whitehawk Therapeutics -March 18, 2025 at 05:58 pm EDT - Marketscreener.com
Aadi Bioscience Inc changes name to Whitehawk Therapeutics - TradingView
Aadi Bioscience Relaunches as Whitehawk Therapeutics Marking Evolution into ADC Company - PR Newswire
Aadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update - Seeking Alpha
Aadi Bioscience Announces Closing of $100 Million PIPE Financing - MarketScreener
WhiteHawk Capital Partners Provides Credit Facility to Nephron Pharmaceuticals - Business Wire
Finance Watch: Generation Bio, CytomX Right-Size Operations Ahead Of J.P. Morgan - insights.citeline.com
Asia Deal Watch: Kaken Obtains Aadi Subsidiary And Cancer Drug Fyarro - insights.citeline.com
PHX Minerals Explores Sale After Rejecting Acquisition Bids - Yahoo Finance
Aadi Bioscience downgraded to Neutral, shares fall (NASDAQ:AADI) - Seeking Alpha
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates - MarketScreener
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update - MarketScreener
Closing Bell: We’ve got a WhiteHawk up as tech takes over ASX200 - Stockhead
Alnylam takes 10% hit on Amvuttra trial tinkering - The Pharma Letter
Transcript : Aadi Bioscience, Inc., Q3 2023 Earnings Call, Nov 08, 2023 - marketscreener.com
Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer - MarketScreener
Transcript : Aadi Bioscience, Inc., Q2 2023 Earnings Call, Aug 09, 2023 - MarketScreener
Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial - Marketscreener.com
Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors - MarketScreener
Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting - MarketScreener
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update - MarketScreener
2.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):